Who paid whom for what — when the target is BCMA, the deal flow is constant, and the asset under the term sheet is a specific binder. US12643952B2, "BCMA/TACI antigen-binding molecules" (Hummingbird Bioscience, issued June 2, 2026), is exactly that kind of asset. The CPC tags — C07K 16/2878 and C07K 16/2803/2809 (antibodies to specific antigens), A61P 35/00 (antineoplastic) — confirm a dual-target oncology binder aimed at myeloma-relevant antigens.
The deals-desk frame: BCMA (and the related TACI) are validated multiple-myeloma targets, which is precisely why binders against them get licensed, optioned, and acquired. An issued composition grant on a specific BCMA/TACI molecule is a bankable asset — it gives a larger developer a defined thing to license rather than a research concept. The structure of any resulting deal, upfront versus biobucks, tracks how de-risked that specific binder is in the clinic.
Upfront versus milestones, read off the asset's maturity: a freshly granted binder that is early in development typically commands a modest upfront and a large contingent "biobucks" tail, because most of the value is still unproven. The headline deal number is not cash; it is the sum of an upfront plus milestones that may never trigger. Reading a grant as if it guarantees the milestones is the classic mis-read this column exists to flag.
What the grant does not convey: clinical validation of this particular molecule, freedom from the dense BCMA antibody landscape, or that the dual BCMA/TACI approach outperforms single-target binders. The myeloma antibody field is crowded; an issued grant carves out a specific molecule's claims but does not clear the surrounding thicket or prove the asset beats its peers.
The disciplined read: when a BCMA deal crosses the desk, identify the specific binder and its issued claims — like this Hummingbird grant — and price the asset that is actually being conveyed. The target is hot, the asset is specific, and the deal terms should reflect how proven the molecule is, not how exciting the target sounds.